Nicotinic acetylcholine receptor (nAChR) subtypes (nAChR)

Nicotinic acetylcholine receptors (nAChRs) are a diverse family of pentameric ligand-gated ion channels that mediate fast excitatory neurotransmission and neuromodulation across the central and peripheral nervous systems (Albuquerque et al., 2009). While the alpha4beta2 and alpha7 subtypes are the most prominent in the brain, the 'other' subtypes encompass a variety of subunit combinations, including alpha2, alpha3, alpha5, alpha6, beta2, beta3, and beta4, as well as the specialized alpha9alpha10 receptors (Gotti et al., 2006). These receptors are critical for regulating the release of neurotransmitters like dopamine, norepinephrine, and GABA, thereby influencing cognitive processes, reward mechanisms, and autonomic functions (IUPHAR/BPS Guide to Pharmacology, 2023). Dysregulation of these miscellaneous subtypes is linked to several pathologies, including nicotine addiction, Parkinson's disease, autonomic dysreflexia, and chronic pain (Changeux, 2010). Pharmacological agents targeting these receptors include a range of agonists, antagonists, and allosteric modulators, many of which are being explored for their potential to treat neuropsychiatric and neurodegenerative conditions (Dani & Bertrand, 2007). However, the high degree of structural homology between subtypes presents a significant challenge for drug development, often leading to off-target effects in the cardiovascular and gastrointestinal systems (Zoli et al., 2018).

Other names

Neuronal nicotinic acetylcholine receptorsnAChRCholinergic receptor nicotinicNon-alpha7 non-alpha4beta2 nicotinic receptorsMiscellaneous nicotinic receptor subtypes

Agonism, antagonism, or allosteric modulation of pentameric ion channels to regulate cation influx (primarily Na+ and Ca2+) and subsequent cellular depolarization (Albuquerque et al., 2009; IUPHAR/BPS Guide to Pharmacology, 2023).